Publication
Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.
Authors not recorded
Mol Cancer Res2014PMID 24962318PMC4482471stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMelanomacivic_curation1.00
- drugAZ909civic_curation1.00
- drugSelumetinibcivic_curation1.00
- geneTBK1civic_curation1.00
- variantTBK1 Overexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24962318
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| TBK1 Overexpression1 | ||||||||
| AZ909 + SelumetinibCombination | Melanoma | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1138Preclinical study in melanoma cell lines. TBK1 depletion (siRNA) inhibited migration and invasion, whereas its constitutive overexpression led to an increase in invasion. In MEK-resistant NRAS mutant … (full text at CIViC) PMID 24962318 · Vu et al., 2014 · Open in CIViC | civic |